buyWeak cluster of 7
Brett Matthew Hall bought $35k of IMRX
CHIEF SCIENTIFIC OFFICER at Immuneering Corp. 13,422 shares at an average of $2.58, traded Jun 20, 2025, filed Jun 24, 2025.
Conviction score
36Value
$35k
13,422 shares
Holdings after
359,318
+4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +6Trade size$35k at market
- 0Relative to holdingsHoldings up 3.9%
- 0Price contextNo price history yet
- +15Cluster7 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001790340-25-000087, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | POpen-market purchase Class A Common Stock | +7,415 | $2.70 | $20k | 353,311 | Jun 24, 2025 |
| Jun 23, 2025 | POpen-market purchase Class A Common Stock | +6,007 | $2.43 | $15k | 359,318 | Jun 24, 2025 |
Related signals
Other insiders at Immuneering Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | IMRXbuy Immuneering Corp | Peter Feinberg director | $36k 5,000 shares | +4% | |
| 38Weak | Immuneering Corp | Diana Hausman director | $20k 5,500 shares | - | |
| 33Weak | Immuneering Corp | Leah R Neufeld CHIEF PEOPLE OFFICER | $2,499 700 shares | +7% | |
| 46Moderate | Immuneering Corp | Benjamin J. Zeskind PRESIDENT AND CEO | $35k 10,000 shares | +0% | |
| 47Moderate | Immuneering Corp | Thomas J. Schall director | $35k 9,500 shares | +22% | |
| 36Weak | Immuneering Corp | Harold Eugene Brakewood Chief Business Officer | $4,804 1,900 shares | +49% | |
| 44Moderate | Immuneering Corp | Peter Feinberg director | $63k 25,000 shares | +22% | |
| 42Moderate | Immuneering Corp | Benjamin J. Zeskind PRESIDENT AND CEO | $50k 21,000 shares | +1% | |
| 49Moderate | Immuneering Corp | Thomas J. Schall director | $89k 40,485 shares | +1396% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.